CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
INCITE aims to enhance cancer immunotherapy by creating a specialized microenvironment for T cell education using advanced 3D microfabrication technology. This approach seeks to generate more effective anti-tumor T cells for adoptive cell therapy, potentially improving treatment outcomes for various cancers.
Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU.
Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century.
Immunotherapy of cancer by checkpoint inhibitors, vaccines or adoptive T cell therapy is coming of age and has the potential to cure cancer, but is still hampered by some major limitations.
For instance, Adoptive Cell Therapy (ACT) with unmanipulated or…
NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Austria, Wien
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Austria, Innsbruck
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
